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Abstract
Background: In malaria endemic countries, children who have experienced an episode of severe anaemia are at increased
risk of a recurrence of anaemia. There is a need to find ways of protecting these at risk children from malaria and
chemoprevention offers a potential way of achieving this objective.
Methods: During the 2003 and 2004 malaria transmission seasons, 1200 Gambian children with moderate or severe
anaemia (Hb concentration ,7 g/dL) were randomised to receive either monthly sulfadoxine-pyrimethamine (SP) or
placebo until the end of the malaria transmission season in which they were enrolled, in a double-blind trial. All study
subjects were treated with oral iron for 28 days and morbidity was monitored through surveillance at health centres. The
primary endpoint was the proportion of children with moderate or severe anaemia at the end of the transmission season.
Secondary endpoints included the incidence of clinical episodes of malaria during the surveillance period, outpatient
attendances, the prevalence of parasitaemia and splenomegaly, nutritional status at the end of the malaria transmission
season and compliance with the treatment regimen.
Results: The proportions of children with a Hb concentration of ,7 g/dL at the end of the malaria transmission season were
similar in the two study groups, 14/464 (3.0%) in children who received at least one dose of SP and 16/471 (3.4%) in those
who received placebo, prevalence ratio 0.89 (0.44,1.8) P=0.742. The protective efficacy of SP against episodes of clinical
malaria was 53% (95% CI 37%, 65%). Treatment with SP was safe and well tolerated; no serious adverse events related to SP
administration were observed. Mortality following discharge from hospital was low among children who received SP or
placebo (6 in the SP group and 9 in the placebo group respectively).
Conclusions: Intermittent treatment with SP did not reduce the proportion of previously anaemic children with moderate or
severe anaemia at the end of the malaria season, although it prevented malaria. The combination of appropriate
antimalarial treatment plus one month of iron supplementation and good access to healthcare during follow-up proved
effective in restoring haemoglobin to an acceptable level in the Gambian setting.
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Introduction
Anaemia remains one of the most important health problems
for children in malaria-endemic countries of Africa; the prevalence
of severe anaemia, usually defined as a Hb,5g/dL, among
children in the community varies from 1.3% to 6.4% [1–6] and
moderate anaemia (Hb,7g/dL) is frequent. Severe anaemia is a
major cause of hospital admission and contributes substantially to
inpatient paediatric mortality and mortality. Among children
admitted to hospital in sub-Saharan Africa the prevalence of
severe anaemia ranged from 7% to 29% in different epidemio-
logical settings [1–6]. The case fatality rate (CFR) for children with
severe anaemia is estimated to be between 8% and 18% [3,4,6–10].
Causes of severe anaemia in African children include nutritional
deficiencies, infections, and haemoglobinopathies. However, infec-
tion with Plasmodium falciparum is one of the main causes in malaria
endemic areas. Malaria infection results in destruction of both
infected and non-infected red blood cells and depresses the ability
of the bone marrow to produce new red blood cells.
Studies in a high malaria transmission area of western Kenya
indicated that children treated for severe anaemia (Hb,5g/dL)
were at high risk of dying after they had been discharged from
hospital due to a rebound of their anaemia [11,12]; 14%–16% of
children treated for severe malaria died at home within eight
weeks of discharge. Ineffective antimalarial treatment and
persistent parasitaemia on discharge from hospital were strong
predictors of subsequent out-of-hospital mortality. In these
settings, effective antimalarial treatment and the targeted delivery
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effective approach to reducing the morbidity and mortality
associated with severe anaemia. These findings indicate that there
is a need to improve the management of African children with
severe anaemia both within hospital and after their discharge.
Prevention of malaria through provision of an insecticide treated
bednet (ITN) is likely to be one effective option. Chemoprevention
offers another potential approach.
Intermittent preventive treatment (IPT), which involves admin-
istration of a full treatment course of an antimalarial at specified
times to at risk subjects regardless of whether or not they are
known to be parasitaemic, was devised as a strategy for
overcoming some of the problems associated with chemoprophy-
laxis whilst taking advantage of its protective effects. IPT was
developed initially for use in pregnant women and then adapted to
malaria control in infants (IPTi) and older children (IPTc). The
role of IPT in the prevention of malaria and anaemia in children
has been evaluated in a number of trials. In Mali, an area of
seasonal malaria transmission, two doses of sulphadoxine-pyri-
methamine (SP) given to children aged 6 months to 9 years at an
interval of two months gave a protective efficacy of 40% against
clinical attacks of malaria [13]. In another study undertaken in
Niakhar, Senegal, an area of intense but short seasonal malaria
transmission, SP and one dose of artesunate (AS) given to children
less than 5 years old three times at one monthly intervals
throughout the peak period of malaria transmission reduced
clinical attacks of malaria by 86% [14]. A further trial was
undertaken in the same study site to compare different treatment
regimens and high levels of efficacy against episodes of clinical
malaria were observed with each treatment regimen [15]. In
another comparative study carried out in Ghana, monthly
amodiaquine (AQ) plus AS was compared with bimonthly AQ
plus AS and bimonthly SP. Monthly AS plus AQ was the most
effective regimen, giving 69% protection against clinical episodes
of malaria [16]. These results suggest that IPTc has potential as an
affordable malaria control tool. However, the potential role of IPT
in the prevention of a recurrence of severe anaemia in children
who have already been treated for moderate or severe anaemia (
Hb,7g/dl) remains to be established. Thus, we have investigated
whether monthly IPT with SP given during the malaria
transmission season can protect Gambian children treated
previously for moderate or severe malaria in hospital against a
recurrence of anaemia.
Methods
The protocol for this trial and supporting CONSORT checklist
are available as supporting information; see Checklist S1 and
Protocol S1. A summary of the recruitment and follow-up
procedures is shown in Fig. 1.
Objectives
The primary objective of the study was determination of the
impact of IPT with SP on the proportion of children previously
treated for severe or moderate anaemia who had a recurrence of
their anaemia at the end of the malaria transmission season.
Secondary objectives included study of the impact of IPT with SP
on the incidence of clinical episodes of malaria during the
surveillance period, outpatient attendances, the prevalence of
parasitaemia and splenomegaly and nutritional status at the end of
the malaria transmission season and compliance with the
treatment regimen.
Study area and population
The study was conducted in the Western Region of The
Gambia, which includes the capital Banjul. Transmission of
malaria in The Gambia is seasonal. The climate is typical of sub-
Sahelian Africa with a long dry season, which lasts from
Figure 1. Overall study design. The duration of follow up varied depending upon the time in the malaria transmission season when a child was
recruited. OPD=outpatient department; Hb=haemoglobin; BF=blood film.
doi:10.1371/journal.pone.0011227.g001
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July–November during which most malaria transmission occurs.
Morbidity and mortality from malaria follow this pattern, both
occurring much more frequently during the rainy season, with
a peak in the month of October. The annual entomological
inoculation rate varies enormously across the country and is in the
range of 1–177 infected bites per person year [17]. During the
course of the study, first line treatment for uncomplicated malaria
in The Gambia changed from chloroquine to the combination of
chloroquine and SP. Since 2008, the recommended first line
treatment for uncomplicated malaria has changed to artemether-
lumefantrine (Coartem
TM, Norvatis Pharma, Basel Switzerland).
In 2001, the PCR-corrected treatment failure rate in symptomatic
children at day 28 after the start of treatment with SP was 6%
[18]. At the time of the study there were no standardized
guidelines for the prevention of anaemia in children.
1200 children were recruited from the Royal Victoria Teaching
Hospital (RVTH), Banjul, the Medical Research Council (MRC)
Hospital, Fajara, or from the major health centres at Brikama,
Essau and Faji Kunda, 600 children during the 2003 transmission
season (July to December), and another 600 children in the 2004
malaria transmission season. The study was extended to include
the WEC clinic, Sibanor, in 2004.
Screening, enrolment and randomization
The trial was designed as an individually randomised, controlled,
double-blind study. Children were recruited on presentation to the
out-patient clinic (OPD) or ward of one of the participating health
facilities. Children suspected of having anaemia and who were in
the right age group had their Hb concentration measured and a
blood film examined for the presence of malaria parasites. Children
were eligible for enrolment if they were aged between 3 months and
9 years and had a Hb concentration ,7 g/dL. Children who did
not meet these criteria were excluded. Individual, signed consent
was obtained from the parents or guardians of children who met the
study inclusion criteria. The randomisation list was generated by a
senior MRC statistician. Provided that consent was given, children
were individually randomized into either the SP or the placebo
group in a 1:1 ratio at the time of admission, using permuted blocks
of 12 generated by computer using the STATA program. Blocks
were not split across centres. Tablets (enough for 6 doses) were
packed into envelopes bearing the randomization number by MRC
staff not involved in the trial in any other way. The next envelope in
sequence was assigned to the child at the time of their admission to
hospital. Copies of the randomization code, kept in a sealed opaque
envelope, were held by the local safety monitor and the MRC
Laboratories accountant. Some additional replacement envelopes
were also prepared, which were separately numbered, with a listing
indicating which of these envelopes should be used in the event that
a child’s envelope was lost or damaged, None of the investigators,
health care centre staff or laboratory staff participating in the trial
had access to the code during the trial. A formal attempt to
demonstrateblinding(byaskingthesubjectstoguesstheir treatment
allocation) was not undertaken. The code was provided to the
investigators onlyafter a lockedcopyof thedatabase hadbeengiven
to the chairman of the Data Safety and Monitoring Board.
Initial case management
On admission, children were clinically evaluated and additional
investigations, for example lumbar puncture, were undertaken
when these were indicated on clinical grounds. The majority of
children with malaria were treated with intramuscular quinine
followed by SP. However, a small number received chloroquine
plus SP. Patients were treated for other conditions as clinically
indicated. Children were kept in hospital until all signs of
respiratory distress had subsided and until their Hb concentra-
tion had increased over that found on admission. Their average
duration of stay in hospital was 4 days (range 1 to 36 days).
Children with a haemoglobin concentration of ,5 g/dL and/or
signs of respiratory distress were scheduled for immediate
transfusion with whole blood in accordance with national
guidelines. All patients received iron for 28 days (ferrous fumerate
syrup at a target dose of 2mg/kg), starting at the time of their
discharge from hospital. Each child was provided with a photo ID
card with their unique study number prior to their discharge from
hospital. Children were asked to return for follow-up 7 days after
discharge. At this visit, a fingerpick blood sample was collected for
Hb concentration measurement and thick blood film examination
for malaria parasites. Any medical condition detected during the
visit was treated appropriately.
Chemoprevention
The first dose of trial medication was given under supervision by
project staff at the first follow-up visit to the hospital or health
centre where the child had been admitted, scheduled to be seven
days after their discharge from hospital. The envelope containing
the trial medication bearing the child’s study number was then
transferred to the health centre closest to the child’s home where
the patient continued to receive monthly chemoprevention given
by trained field workers. Subsequent monthly doses of SP or
placebo were given under the supervision of clinic staff until the
end of the malaria transmission season. Thus, the number of
treatments that a child was expected to receive varied depending
upon the time of the year at which they were recruited. SP tablets
(500 mg sulphadoxine/25 mg pyrimethamine) (Cosmos Ltd.,
Nairobi, Kenya) were given at an approximate dose of 1.25 mg
pyrimethamine/25 mg sulphadoxine per kg. Placebo tablets,
which were identical in shape and colour to the SP tablets,
contained mainly lactose and maize starch. Older children took
the study drugs as tablets, which were swallowed whole or chewed.
Younger children were given their tablets crushed, suspended in
water and administered with a spoon.
Morbidity surveillance during the rainy season
Mothers/guardians were encouraged to take their child to one
of the participating health facilities at any time after discharge
from hospital if their child became unwell. In order to facilitate
OPD visits, transport fares were given to mothers each time a
study subject reported to a health facility. Using this method of
passive surveillance, which best reflects the likely public health
impact of an antimalarial intervention, it was unlikely that a
significant number of cases of severe malaria or other conditions
would have been missed during the study but a larger number of
cases of milder malaria might have been identified using active
surveillance with home visits. A finger prick blood sample was
obtained from any study child who presented with an axillary
temperature $37.5uC or a history of fever within the previous
48 hours for preparation of a thick blood film for microscopy and
blood spots on a glass fibre mat (Wallac, Finland) were obtained
for parasite genotyping. Diagnosis and treatment were recorded in
a standardized form each time a study child was seen at a health
facility. Children with documented fever (axillary temperature of
$37.5uC) or a history of recent fever and malaria parasitaemia
were treated with SP and chloroquine in accordance with Gambia
Government treatment guideline. Children who presented with
severe malaria were treated with IM quinine and those who
presented with uncomplicated malaria within one week of
receiving SP chemoprevention received oral quinine. During
IPT Trial in Anaemic Children
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were treated with iron for a further 28 days if they have completed
their initial iron treatment and those with severe anaemia were
referred for admission. Deaths that occurred at home were
investigated using the post-mortem questionnaire technique and
the cause of death established whenever possible.
Adverse events
All adverse reactions which might be related to drug
administration were documented at each contact with the study
subject. Particular attention was paid to the presence of any skin
reactions, in particular Stevens-Johnson syndrome as this is the
most important adverse reaction related to SP administration.
Cross-sectional surveys
All children were visited in the January after the end of the
transmission season in which they were enrolled. A standardized
questionnaire was administered to collect information regarding
any illness that had occurred since the last visit, use of healthcare
facilities and use of medicines. Information on the use of bednets
was collected during this survey. Children were examined by a
physician, anthropometric data were collected, and a finger-prick
blood sample was obtained for preparation of a thick blood smear
and determination of Hb concentration. At the end of the
following dry season in May, study subjects were visited at home
and a short questionnaire administered to document morbidity
and mortality during the preceding five months.
Laboratory methods
Thick smears were prepared in duplicate so that if the subject
had symptoms of malaria, one smear could be stained with Field’s
stain and read promptly to guide treatment. The other smear was
stained with Giemsa stain and 200 high power fields (HPF) were
examined before a smear was declared negative. Only the Giemsa-
stained slide readings were used for the trial analysis. Parasite
density was expressed per ml with the assumption that 1 parasite
per high-powered field (hpf) equals 500 parasites per ml [19]. All
slides were read by two laboratory technicians. If there was
disagreement between these readings on parasite positivity or if the
difference of the log-densities recorded was more than 1.5, slides
were read by a third technician. Agreement was reached after the
slides had been re-checked. Discrepancies occurred mainly in
smears with very low parasite densities. On rare occasions during
follow-up, when a laboratory technician was not available to read
a thick blood smear for malaria parasites, the Core
TM Malaria Pf
test (CORE Diagnostics, Birmingham, UK) was used to guide
treatment and a thick blood smear collected for subsequent
confirmation of the diagnosis.
Haemoglobin concentration was measured at recruitment,
during morbidity surveillance and at the end of malaria
transmission season surveys using a portable haemoglobinometer
(HemoCue AB, Sweden).
DNA was extracted from glass fibre mats using the chelex
technique [20]. Polymorphisms in the pfdhfr and the pfdhps genes,
associatedwithresistanceto pyrimethamine(codons51,59and 108
of dhfr) and sulphadoxine (codons 437 and 540 of dhps) respectively,
were tested for using PCR amplification followed by restriction
fragment length polymorphism analysis (PCR-RFLP) [21].
Statistical methods
The sample size was determined on the basis of previous studies
carried out in The Gambia. We estimated that 20% of children
would be moderately anaemic (PCV,20% - approximately equal
to a Hb concentration of 7 g/dL) at the end of the malaria
transmission season and that the attack rate of malaria (cumulative
incidence of malaria) in the control group would be 0.1 episodes
per month. To detect a reduction by one third (from 20% to 13%)
in the prevalence of moderate to severe anaemia (Hb,7g/dL) at
the end of the malaria transmission season with a power of 80%,
using a significance level of 5% and assuming 15% loss to follow-
up, 600 children were needed in each group. With this sample size,
the study had 80% power using a 5% level of significance, to
detect a reduction by one third in the incidence of clinical attacks
of malaria in the treatment group. The primary endpoint was the
prevalence of anaemia (Hb,7), the prevalence ratio was
calculated with 95% confidence interval; the log-binomial model
[22] was used to estimate the prevalence ratio adjusted for
covariates (baseline Hb concentration, malaria infection at
baseline, bednet usage and recruitment centre) which were
specified in an analysis plan written before unblinding. In the
primary analysis only children who received at least one dose of
IPT or placebo, and were followed up, were included. Mean
haemoglobin concentration was compared using a t-test, and an
adjusted difference between means was obtained using normal
regression. An episode of clinical malaria was defined as an illness
accompanied by (a) an axillary temperature of $37?5uCo ra
history of fever within the previous 48 hours, (b) no other obvious
cause for the fever and (c) the presence of P falciparum asexual stage
parasitaemia at any density. Malaria with high density parasitae-
mia was defined as above but included only children with a P
falciparum parasite density of $5000/mL. Malaria parasitaemia at
the cross-sectional survey was defined as the presence of asexual
stage P. falciparum parasitaemia of any density regardless of the
presence or absence of the symptomatic criteria used for the
definition of clinical malaria. A serious adverse experience was
defined as any event which was fatal, life threatening, disabling or
incapacitating or resulted in hospitalisation or prolonged a hospital
stay or was associated with overdose (either accidental or
intentional). Adverse events were not formally graded for severity.
Cox regression was used to compare the incidence of malaria, and
of anaemia, between the two groups. Efficacy was defined as the
percentage reduction in the number of events in the intervention
group, estimated as 1006(1-hazard ratio). All events were included
in the analysis and a robust estimator of the variance was used to
allow for the lack of independence among repeated episodes in the
same child. For the malaria endpoint, estimates were adjusted for
the effects of bednet usage defined as sleeping every night under an
intact or impregnated net, recruitment centre and age. For
anaemia, estimates were adjusted for net use, recruitment centre,
baseline prevalence of parasitaemia, and baseline Hb concentra-
tion. Interaction between treatment group and bednet use was
examined for both outcomes. Time at risk started at the beginning
of the surveillance period (the date of the day 7 visit after
discharge) and ended on the last day of December of the same
year. If a subject was lost to follow-up observations were censored
from the date of the first scheduled visit that they failed to attend.
If a subject withdrew consent or died, the observation for that
subject was censored at the date of the death or withdrawal.
Children who moved temporarily out of the study area but
returned to take some of the courses of treatment remained as part
of the study cohort. Analyses were done using STATA version 10
(STATA Corporation, TX, US).
Ethical review
The study was approved by the London School of Hygiene &
Tropical Medicine Ethics Committee and by the joint MRC/
IPT Trial in Anaemic Children
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was guided by a Data Safety and Monitoring Board.
Results
During the two-year study period, 5917 children with pallor
who presented at the five trial sites were screened. 1200 eligible
children were enrolled (600 during each year of the study,
Figure 2). The remaining children were not enrolled because they
did not meet the inclusion criteria or had one of the exclusion
criteria. Recruitment started in August during the first year of the
study and in July during the second year, but the majority of study
subjects (80%) were recruited during the peak period for malaria
transmission (September, October and November) and thus were
eligible to receive only 2 or 3 treatments with SP. 546/600 (91.0%)
and 539/600 (89.8%) of the children enrolled into the SP and
placebo groups on admission to hospital received their first dose of
trial medication. Among the 54 children in the SP group who were
not seen at the day 7 visit, 45 were lost to follow-up, 7 died and 2
subjects were withdrawn by their families. In the placebo group,
61 did not come for the day 7 follow-up and of these 52 were lost
to follow-up, 7 died and 2 were withdrawn by their families. 951/
1200 (79%) subjects were seen at the end of the malaria
transmission season, of these 942 had received at least one dose
of IPT or placebo. 966/1200 (80%) subjects were seen at the end
of the following dry season.
Baseline characteristics of the study children
Baseline characteristics of enrolled patients were similar for the
two treatment groups (Table 1). The prevalence of malaria
parasitaemia in the SP and placebo groups were 62% and 61%
respectively and mean parasite densities were similar in each
group (Table 1). In addition, there were more children in the
placebo group who had splenomegaly compared to the SP group.
More children in the SP group slept under a bednet compared to
children in the placebo group when bednets were inspected at the
end of the transmission season.
Figure 2. Trial profile.
doi:10.1371/journal.pone.0011227.g002
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Fourteen of the 1200 children enrolled died in hospital before
receiving their first dose of trial medication (7 in each group). Two
had pneumonia, one developed cerebral malaria, and 11 died of
severe anaemia. Nine children died despite having received a blood
transfusion. At the day 7 follow-up, the prevalence of malaria
parasitaemia in the SP and placebo groups was 29/546 (5.3%) and
25/539 (4.6%) respectively. These patients were asymptomatic and
most had only low-level parasitaemia. Mean haemoglobin (SD)
concentrations 7 days after discharge were also similar in the two
treatment groups [7.51 (3.6) g/dL and 7.45(3.3) g/dL]. 12.5% and
13% of the childrenin the SP and placebo groups had haemoglobin
concentration of less than 5g/dl at the day 7 follow-up visit.
Compliance with IPT
Because administration of IPT was terminated at the end of the
malaria transmission season, the number of times that a child
should have received SP or placebo varied from 1 to 6 (Table 2).
Compliance was initially high but decreased progressively in
children who were required to take the most doses.
Overall impact of IPT on mortality, morbidity and
nutritional status
Between the time of first administration of IPT and the end of
the malaria transmission season, six children died (2 in the SP
group and 4 in the control group). In the SP group, one child died
of severe anaemia and another died of severe malaria. In the
placebo group, four children died of severe malaria. Nine children
died during the dry season following the period in which IPT was
given, 4 in the SP group and 5 in the placebo group. In the SP
group, two children died of severe anaemia and one each of
malnutrition and acute respiratory infection. In the placebo group,
2 children died of severe malnutrition and one each of HIV
infection, a road traffic accident and severe anaemia. Thus, overall
there were 6 deaths in children who received SP and 9 in those
who received placebo.
Twelve study children were re-admitted to one of the health
facilities in the study area during the follow-up period; 5 and 7 in
the SP and placebo groups respectively. Three children were
admitted because of severe anaemia; one in the SP and two in the
placebo group. One of the children in the placebo group was
admitted on two occasions because of severe malaria anaemia.
The protective efficacies of the intervention against various
morbidity endpoints detected during outpatient or dispensary
visits are shown in Table 3. There were 257 visits to the OPD in
the placebo group and 184 in the SP group, a reduction of 29%
(95%CI 13%,42%). The intervention provided 43% (20%,59%)
efficacy against episodes of documented fever (axillary temperature
of $37.5uC). Protective efficacy against upper respiratory
infection, skin/soft tissue infection and gastroenteritis was 21%,
17% and 41% respectively. However, the numbers of these events
were small and corresponding 95% confidence intervals are wide.
Children who had received IPT with SP were better nourished
at the end of the malaria transmission season than children who
had received placebo. Weight-for-height and mid upper arm
circumference were significantly higher in the SP than in the
placebo groups at the December cross-sectional survey (Table 4).
Protective efficacy of IPT against anaemia
The proportions of children with a Hb concentration of ,7g /
dL at the end of the malaria transmission season, the primary trial
endpoint, were similar in the two groups of children, 14/464
(3.0%, 95%CI 1.5%, 4.6%) in children who received SP and 16/
471 (3.4%, 95%CI 1.8%, 5.0%) in those who received placebo
(prevalence ratio 0.89 (0.44,1.8) P=0.742). Only one child, in the
placebo group, had a Hb concentration of ,5g/dL. The mean
haemoglobin (SD) concentration at the end of the malaria
transmission season was slightly higher in children in the SP
group [10.8 (1.7) g/dL ] compared to the placebo group [10.6
(1.8)g/dL ], difference 0.23 (0.002,0.45) P=0.048 (adjusted for
baseline Hb and other covariates) but this difference is unlikely to
have been clinically significant. The cumulative number of
children who had anaemia (Hb,7g/dL) at OPD visits during
surveillance or at the end of the transmission season was 32/470
(6.8%) in the SP group and 42/477 (8.8%) in the placebo group
(ratio 0.77 (0.50,1.2) P=0.252), and of these 4/465 (0.9%) had
Hb,5 in the SP group compared to 11/462 (2.3%) in the placebo
group (ratio 0.37 (0.12,1.2) P=0.074). Similar results were
obtained after adjusting for covariates (Table 3); there was no
evidence of an interaction between treatment group and bednet
use.
Table 1. Admission characteristics of children in the two
study groups.
Variable SP Placebo
**N=597 **N=598
Age (months)
(mean, SD) 28.4 (18) 28.7 (19)
Sex (male) % 52.3% 52.1%
Ethnic group
Mandingo 228(39%) 227(38%)
Wollof 74 (13%) 91 (15%)
Fula 98 (17%) 96 (16%)
Jola 85 (14%) 88 (15%)
Others 102 (17%) 93 (16%)
Recruitment centre
RVTH 160 (27%) 166 (28%)
MRC 117 (20%) 114 (19%)
Brikama 155 (26%) 152 (26%)
Essau 124 (21%) 126 (21%)
Sibanor* 36 (6%) 36 (6%)
Previous chloroquine treatment (%) 62.4 60.6
Educational attainment of mother
(years in school), (mean, SD)
2.1 (5.7) 2.0 (3.6)
Resp rate/min (mean, SD) 40.0 (13) 39.3 (12)
Mean haemoglobin g/dl (SD) 5.1 (1.2) 5.2 (.053)
Temp uC (mean, SD) 37.5 (0.91) 37.56 (.88)
Pulse rate/min (mean, SD) 121 (21) 120 (21)
Splenomegaly (%) 19.8 24.7
Hepatomegaly (%) 26.7 27.2
Proportion with malaria parasitaemia 62% 61%
Geometric mean density
(95% CI)
IQR
17710
(136223, 23024)
(0, 51000)
15296
(11668, 20050)
(0, 47600)
Sleeps nightly under intact or
impregnated net#
20.7 15.3
*Recruitment only during year 2.
**Data missing for 2 and 3 subjects in the placebo and SP groups respectively.
#bednet use was determined at the end of the transmission season.
doi:10.1371/journal.pone.0011227.t001
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considered, the prevalence of moderate to severe anaemia
(Hb,7 g/dL) at the end of the transmission season was slightly
higher among children who had been transfused (5/43 (14.7%) in
the placebo group compared to 2/30 (6.67%) in the SP group) but
there was no evidence of interaction between intervention group
and having been transfused (P=0.350).
Protective efficacy of IPT against malaria
During the malaria transmission season following enrolment,
there were 30 episodes of malaria with high parasitaemia (.5000/
ml) in children who received SP compared to 68 in those who
received placebo, a protective efficacy of 56% (30%,73%). When
all episodes of malaria are considered, 91 episodes of clinical
malaria were recorded in children who received SP compared
with 192 in children who received placebo giving an efficacy of
53% (37%,65%)[Table 5]. There was no evidence of an
interaction between treatment group and bednet use. Figure 3
shows the timing of first episodes of malaria in each group (logrank
test: P,0.001).
Seventy-two of 460 children (16%) in the SP group had asexual
stage P.falciparum parasitaemia compared with 119/473 (25%) in
the control group (prevalence ratio 0.62 (0.48,0.81) P,0.001) but
very few children in either group had a parasitaemia of $5000/mL
(6 (1.3%) SP, 16 (3.4%) placebo, prevalence ratio 0.39 (95%CI
0.15,0.98) P=0.037). There was a statistically significant differ-
ence in the prevalence of splenomegaly between the two groups at
this time point but the prevalence of splenomegaly was low in both
groups (2.9% in SP vs 6.5% in placebo group)( p=0.006).
Interviews with mothers suggested that 46 and 50 children in
the SP and placebo groups respectively received antimalarial
treatment during the dry season.
The effect of the intervention on parasite genotypic
markers of resistance to SP
One hundred and ninety-five (75%) and 182 (70%) of 259 first
positive samples collected at enrolment were successfully analysed
for polymorphisms in dhfr (codons 51, 59, and 108) and dhps (codon
437 and 540) genes respectively. The numbers genotyped among
78 samples collected from parasitaemic children during the
December cross-sectional survey were 58 (74%) and 44 (56%)
for the two genes respectively. The remainder were not analysed
because there were no detectable PCR products. The prevalence
of triple mutations in the pfdhfr gene associated with pyrimeth-
Table 2. Number of doses of trial medication received and compliance (percentage).
Dose number SP Placebo
Number of children
scheduled to receive
the dose
Number of children
that received the
dose
*Percentage
Compliance
Number of children
scheduled to receive
the dose
Number of children
that received the
dose
*Percentage
Compliance
1 600 546 91% 600 539 90%
2 520 409 79% 514 410 80%
3 327 222 68% 321 224 70%
4 173 101 58% 168 99 59%
5 71 27 38% 64 29 45%
6 9 2 22% 9 3 33%
doi:10.1371/journal.pone.0011227.t002
Table 3. Morbidity during the malaria transmission period in children who received at least one dose of SP or placebo.
Outcome SP Placebo
Protective efficacy#
(95% CI) P value
Events
Person
months
at risk
Incidence
rate*/100
person
months Events
Person
months
at risk
Incidence
rate*/100
person
months
Total outpatient visits 184 1288.2 14 257 1279.4 20 29% (13%,42%) 0.001
OPD visits with fever (temp
$37.5uC)
59 1288.2 4.6 102 1279.4 8.0 43% (20%,59%) 0.001
Anaemia (Hb,7g/dL) 19 1288.2 1.5 24 1279.4 1.9 21% (249%,58%) 0.466
Anaemia (Hb,5g/dL) 2 1288.2 0.16 9 1279.4 0.70 78% (23%,95%) 0.055
Upper respiratory tract infection 50 1288.2 3.9 63 1279.4 4.9 21% (218%,47%) 0.248
Skin/soft tissue infection 25 1288.2 1.9 30 1279.4 2.3 17% (255%,56%) 0.558
Gastroenteritis 9 1288.2 0.70 15 1279.4 1.2 41% (233%,74%) 0.207
*Incidence from the date of first dose of IPT with SP or placebo up to the end of December the same year.
#estimated as 1006(1-HR) where HR is the hazard ratio from Cox regression, without covariate adjustment. Efficacy against anaemia Hb,7, adjusted for effects of
bednet use, centre, baseline haemoglobin concentration and presence of parasitaemia at baseline was 8.2% (95%CI 281%,53%), compared with an unadjusted estimate
among the subset of individuals with non-missing covariate data of 13% (269%,56%).
doi:10.1371/journal.pone.0011227.t003
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period of surveillance in children who received monthly SP, from
87% (72/83) at the time of clinical presentation to 100% (14/14)
at the end of season, and in those who received placebo from 82%
(92/112) at the time of clinical presentation to 95.5% (42/44) at
the end of season. Neither of these increases were statistically
significant (p=0.32 and p=0.06 respectively). The prevalence of
the codon 437 mutation in the pfdhps gene associated with
resistance to sulphonamides did not change significantly during
the study period in either arm of the study. For the SP treatment
group, the prevalence was 49% (39/79) at the time of enrolment
and 21% (3/14) in December (p=0.1), and in the placebo group
the prevalence was 48.5% (50/103) at the enrolment and 37%
(11/30 (37%) in December (p=0.35). The 540E allele in the dhps
gene associated with sulphonamide resistance was not present in
the study population.
Safety and tolerability
No severe skin reactions suggestive of the Stevens Johnson
syndrome were seen. Minor symptoms recorded during the 30
days after the administration of each treatment were similar in the
SP and placebo groups (data not shown). No child was withdrawn
from the study because of an adverse event due to SP.
Discussion
Intermittent preventive treatment (IPT) was developed first as a
strategy to control malaria in pregnancy and then adapted to
malaria control in infants and older children. We have further
extended this approach to anaemic children because this group
represent a vulnerable group who could benefit from a highly
effective malaria control strategy.
We did not find that monthly treatment with SP had any
significant impact on the prevalence of moderate or severe
anaemia in previously anaemic children followed through a
malaria transmission season, the primary endpoint for this trial.
Less than 4% of children in either the intervention or the control
group had a Hb concentration of less than 7 g/dL when seen at
the end of the malaria transmission season. Children in the
intervention group did have a higher mean haemoglobin
concentration than the control children (10.8g/dL vs 10.6g/dL),
a difference that is unlikely to be clinically important. Thus, in The
Gambia, an area of moderate malaria endemicity and highly
seasonal transmission, provision of oral iron supplementation for a
four-week period and ready access to a health facility seem
adequate to prevent previously anaemic children from relapsing.
In our study, iron supplementation was given for only one month,
a decision based in part on the result of a previous pilot trial
carried out at RVTH, Banjul which showed that the mean PCV
was significantly higher in children with severe anaemia who
received one month of iron supplementation than in those treated
by blood transfusion alone and that by the end of the malaria
transmission season a majority of the children treated with iron
had normal haemoglobin concentrations [5]. In an study
undertaken in young children with anaemia in Tanzania, it was
shown that children who received iron supplementation and
monthly SP for three months had a lower prevalence of anaemia
than those who received these interventions for only a month but
the difference between groups was modest and interpretation of
the results of this trial is complicated by differences in the duration
of follow-up [23]. Sustaining compliance with iron supplementa-
tion for three months would be difficult and there are concerns
that iron supplementation may increase the risk of malaria in
highly endemic areas [24].
The overall prevalence of moderate anaemia at the end of the
malaria transmission season in children previously treated for
Table 4. Anthropometric findings at the end of the malaria
transmission season.
Anthropometric measurement
(mean, SD) SP Placebo P value
Height-for-age (z score) Mean (SD) 20.51 (1.1) 20.59 (1.4) 0.31
Weight-for-height (z score) Mean (SD) 20.87 (1.2) 21.03 (1.3) 0.04
Weight-for-age (z score) Mean (SD) 20.86 (1.5) 20.93 (1.4) 0.32
Mid upper arm circumference (cm)
Mean (SD)
14.91 (1.9) 14.67 (1.5) 0.02
Stunted 10.9% 18.5% 0.02
Underweight 22.8% 24.4% 0.58
Wasted 17.7% 20.7% 0.28
doi:10.1371/journal.pone.0011227.t004
Table 5. Incidence of malaria during the malaria transmission period among children who received at least one dose of IPT.
Outcome SP Placebo
Protective efficacy#
(95% CI) P value
Events
Person
months
at risk
Incidence rate*/
100 person
months Events
Person
months
at risk
Incidence rate*/
100 person
months
All episodes with .5000 parasites
per mL
30 1288.2 2.3 68 1279.4 5.3 56% (30%,73%) 0.001
All episodes of clinical malaria 91 1288.2 7.1 192 1279.4 15 53% (37%,65%) ,0.001
First or only episode with .5000
parasites per mL
26 1244.9 2.1 60 1184.6 5.1 58% (33%,73%) ,0.001
First or only episode of clinical
malaria
70 1170.0 6.0 133 1054.4 13 52% (36%,64%) ,0.001
#estimated as 1006(1-HR) where HR is the hazard ratio from Cox regression, without covariate adjustment. Efficacy against the first episode of malaria, adjusted for
effects of bednet use, centre and age at enrolment was 54% (37%,66%), compared with an unadjusted estimate among the subset of individuals with non-missing
covariate data of 51% (33%,64%). The corresponding estimates for the first episode of malaria .5000/uL were 58% (31%,74%), compared with 56% (28%,73%)
unadjusted; for all episode of malaria, 52% (38%,63%) compared to 50% (33%,63%) unadjusted; and for all episodes of malaria .5000/uL, 58% (32%,74%), compared to
55% (27%,73%) unadjusted.
doi:10.1371/journal.pone.0011227.t005
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based on previous experience in The Gambia. This may be due to
the fact that the incidence of malaria in The Gambia began to fall
at about the time that this study was conducted [25] so that
malaria has become a much less important cause of anaemia than
was the case 10 or more years ago when earlier studies were done.
If this is the case then SP would not be expected to have a
significant effect on the prevalence of anaemia although remaining
partially protective against malaria.
We did not observe the high rate of recurrence of anaemia and
the associated mortality observed in previous studies in Kenyan
when children with severe anaemia were followed up following
their discharge from hospital [11,12]. The mortality rate during a
period of approximately 6 months following discharge from
hospital was 1.1% in the SP group and 1.7% in the placebo group.
This difference might be due in part to differences in enrolment
criteria. In our study, children with moderate or severe anaemia
(Hb,7g/dL were enrolled whilst the Kenyan trials enrolled only
children with severe anaemia (Hb,5g/dl). Severe anaemia is
associated with an increased risk of death [26] but there is less
evidence of increased mortality associated with moderate anaemia
[26,27]. Another important difference between the two study areas
is the pattern of malaria transmission. In The Gambia, malaria is
seasonal and most cases of anaemia occur towards the end of the
malaria transmission season so that much of the follow-up period
occurred during the period when very little malaria transmission
was taking place. In contrast, malaria transmission is higher and
more perennial in the area of Kenya where the previous
observations were made. In The Gambia, the majority of the
children with severe anaemia were treated with quinine and SP.
Both these drugs remain effective and eliminated parasitaemia in
nearly all cases. Studies in Kenya have shown that persistent
parasitaemia at the time of discharge and during follow-up due to
only partially effective antimalarial treatment are a strong
predictor of post-discharge mortality [11,12,28]. All the children
enrolled in the Gambian study had easy access to health care
during the study period and this could also have contributed to the
low mortality observed.
Despite its lack of a significant impact on anaemia, IPT with SP
was partially effective at protecting against clinical attacks of
malaria with a protective efficacy of 56%. The fact that the
protective efficacy was not higher should not be taken as an
indicator of SP resistance as efficacy measurements included
children who received no drug or who spent several months
without drug cover. A formal analysis of day 28 parasite clearance
rate following SP treatment would almost certainly have given a
higher efficacy figure. Administration of a total of 1700 doses of SP
to 546 children (on an average of 3.1 occasions per child)
prevented 101 episodes of malaria during an average period of
follow up of 2.7 months, a saving of 1 clinical episode of malaria
for every 17 doses of SP given, a figure comparable to that seen in
studies of IPTi. The reduction in the number of clinical episodes of
malaria was associated with a 27% reduction in the overall
number of clinic visits during the follow-up period and children
who received SP were better nourished than those who received
placebo, consistent with findings in other studies of IPT in children
[29]. Deaths and hospital admissions were fewer in children who
received SP than in those who received placebo but numbers of
events are too small for conclusions to be drawn.
The level of protection against clinical malaria episode observed
in this study is similar to that observed in two other previous
studies of IPT in Kenyan children with mild to moderate anaemia
[30,31]. In the first study, conducted in 328 afebrile children aged
2–36 months who had a haemoglobin concentration of between
Figure 3. Kaplan Meier estimates of the cumulative incidence of malaria.
doi:10.1371/journal.pone.0011227.g003
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the number of attacks of clinical malaria (hazard ratios of 0.59 and
0.76 respectively) but the number of episodes of malaria was small
and this reduction was not statistically significant [31]. In a second
trial conducted in 546 children aged 2–36 months who had a
haemoglobin concentration of 70–110 g/dL were enrolled.
Clinical attacks of malaria were again reduced by about a half
in children who received SP alone (hazard ratio of 0.47) but the
difference from the placebo group was not statistically significant
(p=0.07) [30]. Thus, these two trials showed similar point
estimates of levels of protection with chemoprevention with SP
to those observed in the Gambian study although the confidence
intervals were wide.
The possibility that large-scale drug administration on a regular
basis will enhance the spread of drug resistance is a concern for
malaria control by chemoprophylaxis or IPT but our study was
not powered to address this issue, and so our results on the
prevalence of markers of resistance must be interpreted with
caution. Among the samples examined on enrolment there was a
high prevalence of the triple mutation allele at codons 108, 51 and
59 in the dhfr gene associated with pyrimethamine resistance in
both the SP and control groups, and these frequencies increased
during the malaria transmission season in both groups. The 437G
allele in the pfdhps gene associated with resistance to sulphon-
amides did not increase in frequency, and the 540E allele in the
dhps gene was not present in this population. We cannot ascertain
whether the increased in molecular markers of resistance to
pyrimethamine was related to the intervention or an indication of
a more general process taking place in the study area.
Compliance was high among study subjects who were scheduled
to take three or less doses of the trial medication. However, for study
subjects who were scheduled to take more than three doses,
compliance was initially high but decreased progressively with a
tendency for this effect to be more marked in children in the SP
group. However, overall there was no significant difference in
complianceobservedbetweentheSPandplacebogroupssuggesting
that SP did not induce any adverse effects that were of concern to
the mother or guardian. During the study, treatment was available
to study subjects free of charge and parents were provided with
transport money so lack of funds was not the cause of the low
compliance associated with increased doses taken. Distance from a
health facility was also not a likely cause as most of the study area is
urban/peri-urban with relatively good access to health facilities. It is
more likely that the decrease in compliance seen with increased
length of follow-up was due to general apathy towards the project.
Before an intervention such as this could be implemented widely,
issues relating to compliance need to be investigated and an
extensive education programme would be needed.
SP was well tolerated and no severe skin reactions or other
treatment related adverse event was reported. These finding are
encouraging and are similar to those previously reported on the
safety of SP in African children when used for IPTi [32] or IPTc.
Weaknesses of the study include the fact that majority of the
study children received their treatment towards the end of the
season so these children received only one or two doses of
intermittent treatment decreasing our ability to discriminate
between groups. In addition, a recent pharmacokinetic study
suggests that current dosing of sulfadoxine-pyrimethamine in
young children is inadequate and that children aged 2–5 years
should be treated with 1 g sulphadoxine and 50 mg pyrimeth-
amine to achieve drug concentrations equivalent to those needed
in adults for treatment of uncomplicated malaria [33]. This could
have resulted in some study children receiving lower than
recommended doses of SP reducing the protective efficacy of
IPTc.
In The Gambia, intermittent administration of SP to children
previously admitted to hospital with anaemia did not have a
clinically important impact on their haemoglobin concentration by
the end of the transmission season although it did protect against
malaria. Different results may be obtained in areas where
transmission of malaria is higher and perennial.
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